Nodality, Inc. Showcases Novel, Proprietary Technology to Predict Response to Therapy and Relapse Risk in Cancer Patients
Published: Dec 07, 2010
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., developing highly predictive tests to enable biologically informed clinical treatment decisions, today announced the presentation of promising data related to the application of the company’s novel, proprietary technology, Single Cell Network Profiling (SCNP) in hematologic malignancies. SCNP measures the activation levels of signaling networks at the single cell level by measuring the effects of multiple modulators, including drugs, on signaling pathways. This unique functional approach allows for the identification of the underlying heterogeneity in individual patient disease biology and enables efficient classification of patients into therapeutically relevant disease sub-populations by associating cell signaling with the pathogenesis of cancer. Data highlighting the clinical application of SCNP in patients with acute myeloid leukemia (AML) were presented today at the 52nd annual meeting of the American Society of Hematology (ASH) in Orlando, Florida.